Source: BioSpace

Verastem: Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress

Announced Path Forward for VS-6766 and Defactinib Combination Following Meeting with FDA Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Company Monetizes COPIKTRA ® (duvelisib) Providing Cash Runway Until at Least 2024 BOSTON--( BUSINESS WIRE )-- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutic

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Brian Stuglik's photo - CEO of Verastem

CEO

Brian Stuglik

CEO Approval Rating

66/100

Verastem is a biopharmaceutical company that researches, develops and commercializes novel therapeutics for the treatment of cancer. Read more